Current Oncology (Dec 2020)

Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant

  • Karine Moineau-Vallée,
  • Justine Rinfret,
  • My Hanh Luu Hoai,
  • Valérie St-Louis,
  • France Berthelet,
  • Laurent Létourneau-Guillon,
  • Émilie Lemieux-Blanchard,
  • Alexandre Prat,
  • Jean-Philippe Adam

DOI
https://doi.org/10.3390/curroncol28010022
Journal volume & issue
Vol. 28, no. 1
pp. 203 – 208

Abstract

Read online

Natalizumab is used as a second-line treatment for multiple sclerosis (MS). Some reports have linked natalizumab to primary central nervous system lymphoma (PCNSL), although few have described its management. A 45-year-old woman with Balo’s Concentric Sclerosis presented dizziness, vertigo accompanied by dysarthria, weakness on the left side and blurred vision to the right eye after the fourth dose of natalizumab. Magnetic resonance imaging (MRI) and a brain biopsy confirmed the diagnosis of PCNSL. The patient received modified PCNSL chemotherapy (MATRix protocol) followed by high-dose chemotherapy (HDC) supported by an autologous hematopoietic stem cell transplant (ASCT) as a consolidation therapy. Thirty months later, she is still in complete remission of her PCNSL and MS. In this case, whole brain radiotherapy was excluded because it may be associated with an increased risk of neurotoxicity in MS. ASCT was preferred because it has been shown to prevent disability progression in less advanced MS stages. Our patient is the second to receive an ASCT in this context and this option of treatment should be the preferred if the patient is eligible.

Keywords